quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:15:00·72d
PRRelease
Biofrontera Inc. logo

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

BFRI· Biofrontera Inc.
Health Care
Original source

Companies

  • BFRI
    Biofrontera Inc.
    Health Care

Recent analyst ratings

  • Dec 15UpdateBenchmark$11.00
  • Nov 24UpdateRoth Capital$20.00

Related

  • SEC35d
    SEC Form 10-K filed by Biofrontera Inc.
  • SEC36d
    Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR36d
    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
  • PR45d
    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
  • SEC46d
    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR46d
    Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
  • INSIDER48d
    SEC Form 4 filed by Director Weber Kevin Daniel
  • INSIDER48d
    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022